|
07 Jan 2021 |
REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes
|
|
06 Jan 2021 |
Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma
|
|
06 Jan 2021 |
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
|
|
06 Jan 2021 |
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
|
|
06 Jan 2021 |
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
|
|
05 Jan 2021 |
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
|
|
05 Jan 2021 |
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
|
|
05 Jan 2021 |
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
|
|
05 Jan 2021 |
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
|
|
05 Jan 2021 |
Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development
|
|
05 Jan 2021 |
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
|
|
05 Jan 2021 |
Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
|
|
05 Jan 2021 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
|
|
05 Jan 2021 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
|
|
05 Jan 2021 |
Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer
|
|
30 Dec 2020 |
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
|
|
29 Dec 2020 |
Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS
|
|
28 Dec 2020 |
Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
|
23 Dec 2020 |
Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
|
|
23 Dec 2020 |
Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
|
|
23 Dec 2020 |
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
|
|
23 Dec 2020 |
Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Canc
|
|
23 Dec 2020 |
Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review
|
|
22 Dec 2020 |
Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola
|
|
22 Dec 2020 |
Update on SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma
|
